For example, in melanoma patients treated with anti-PD-1 or anti-PD-L1 therapies, those with PD-L1 expression levels greater than 1% showed response rates of approximately 45–50%, compared to 10–15% in patients with low or no PD-L1 expression [181]. This evidence concerns the gene PDCD1 and melanoma.